SDGR

Schrödinger, Inc. [SDGR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SDGR Stock Summary

Top SDGR Correlated Resources

SDGR

Top 10 Correlated ETFs

SDGR

Top 10 Correlated Stocks

SDGR

In the News

SDGR Financial details

Company Rating
-
Market Cap
1.91B
Income
40.72M
Revenue
216.67M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
867
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
49.39
Forward P/E
-
PEG
-3.87
P/S
10.96
P/B
3.87
P/C
-
P/FCF
-15.99
Quick Ratio
5.03
Current Ratio
5.21
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.58
EPS next Y
-
EPS next Q
-
EPS this Y
-127.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
20.43%
Revenue Q/Q
74.13%
EPS Q/Q
-50%
-
-
-
-
SMA20
16.41%
SMA50
12.53%
SMA100
27.32%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
8%
ROC
-0.26%
Gross Margin
61%
Oper. Margin
-88%
Profit Margin
22%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
20.76-59.24
52W High
-61.63%
52W Low
+13.2%
RSI
43.67
Rel Volume
1.4
Avg Volume
888.46K
Volume
1.24M
Perf Week
-7.55%
Perf Month
7.04%
Perf Quarter
10.65%
Perf Half Y
12.69%
-
-
-
-
Beta
1.566
-
-
Volatility
1.12%, 2.49%
Prev Close
-5.67%
Price
22.64
Change
-12.28%

Something similar

Top by Market Cap
ABEA.DE
M&M.NS
NVDA
TSLA
LLY.DE
Top Correlated ETFs
DTEC
ZECP
EQTY
DIA
FDN
Top Correlated Stocks
GNTY
SMBK
MMM
WIT
REPL
Similar Market Cap
CCHHL.NS
BSCL
AGOZX
FGNA
003015.SZ

Company Profile

Healthcare Medical - Healthcare Information Services
  • Volume Average 888.46K
  • Market Capitalization 1.91B
  • Employee 867
  • CEO Dr. Ramy Farid Ph.D.
  • Headquarters New York,NY,US
  • IPO Date 2020-02-06
  • Website https://www.schrodinger.com

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.